Vischer advised Oculis SA on the deal, while Walder Wyss advised Hyfinity Investments.
Oculis S.A., a late-stage biopharmaceutical company focused on developing transformative ophthalmic treatments to improve the sight and lives of patients, has closed an oversubscribed USD 57m Series C financing round.
The round was co-led by new investors BVCF Management and Hyfinity Investments, with VI Partners and Wille AG joining the company’s existing investors, Bay City Capital, Brunnur Ventures, EarlyBird, funds managed by Tekla Capital Management, Pivotal bioVenture Partners, Nan Fung Life Sciences, Novartis Venture Fund, Silfurberg, as well as other existing investors. This excellent syndication further broadens Oculis’ strong shareholder base of leading life sciences investors from the US, China and Europe.
Proceeds from this financing will accelerate Oculis’ strategy with the aim of delivering key goals in the near-term to drive shareholder value and bring transformative therapies to patients.
The VISCHER-team advising Oculis was led by Matthias Staehelin (Picture – Partner) with Vincent Reardon (Managing Associate) (both Corporate).
The Walder Wyss team included Alexander Gutmans (Partner, Corporate/M&A and Venture Capital) and Karina Tschon (Associate, Corporate/M&A and Venture Capital).